Dr. Yusuf, a graduate of St. John's Medical College, Bangalore University, India, was awarded a Rhodes Scholarship that took him to Oxford where he completed a doctorate and underwent clinical training in cardiology. In 1984, he moved to the National Institutes of Health as a scientific project officer of several landmark studies (SOLVD, DIG, and the post-CABG studies) and as Chairman of the working group for the Women's Health clinical trial.

Dr. Yusuf became Acting Chief of the Clinical Trials Branch of the National Heart, Lung, and Blood Institute (NHLBI) and held a number of appointments at the Uniformed Services, University of Health Sciences. In 1992, Dr. Yusuf became Director of the Division of Cardiology, McMaster University, and Director of the Preventive Cardiology and Therapeutic Program, Hamilton Civic Hospitals Research Centre; in 1999, he became the Director of the Population Health Research Institute; he is also Professor of Medicine. Recently, he has been the principal investigator and chairman of several major trials such as HOPE, OASIS, RESOLVD, INTERHEART, SHARE, etc. Dr. Yusuf has conducted studies in Canada, India, and 50 other countries examining why individuals of different ethnic backgrounds experience different heart disease rates.

As Professor and Director of Cardiology he is also lead clinical investigator on the CURE study ( C lopidogrel in U nstable Angina to Prevent R ecurrent Ischemic E vents), a large-scale international trial, investigating antiplatelet therapy in acute coronary syndrome.

He holds an endowed Chair for Research from the Heart and Stroke Foundation of Ontario and is a senior scientist of the Canadian Institute of Health Research. Dr. Yusuf has published more than 300 papers, and edits the Journal of Evidence-Based Cardiology and Textbook of Evidence-Based Cardiovascular Medicine.

Dr. Yusuf received many international awards in the areas of thrombolysis, antithrombotics, prevention of vascular diseases, congestive heart failure, and meta-analytic approaches to the evaluation of clinical trials. These include the Durrer Lecturer (1988), Professional of the Year, Indo-Canadian Chamber of Commerce (1996), NIH Group Award (1992), Sol Sherry Lecturer Award from the International Society of Thrombosis and Hemostasis (1999), Honorary fellowship of the Polish Cardiac Society 91995) and Venezuelan Cardiac Societies (1999), and the Research Achievement Award of the Canadian Cardiovascular Society (1999).

Dr. Yusuf has trained several researchers who are now active in several parts of the world.

Return to top of page


Dr. Gianni Tognoni received his Philosophy Doctor with full honors cum Laude, University of Rome, 1964 and his M.D. with full honors cum Laude, University of Milan, 1970. He is currently Head, Laboratory of Clinical Pharmacology and Coordinator, Department of Cardiovascular Research, Mario Negri Institute, Milano and Laboratory of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH).

Dr. Tognoni's areas of interest include randomised clinical trials, monitoring and epidemiological evaluation of drug effects, methods for assessing quality of care and pharmacoeconomics, research methodology in general hospital and community practice, nursing research and technology transfer and drug policy in developing countries.

Main fields of interest for Dr. Tognoni include cardio-cerebrovascular and peripheral artery diseases, primary and secondary prevention, menopause and diabetes.

Dr. Tognoni has been a member of the Steering Committee of the GISSI trials since 1983 and is an editor of several books and more than 300 articles in medial journals.

Return to top of page


Dr. Mehta obtained his Doctor of Medicine degree from the University of Toronto in 1991. He subsequently undertook Internal Medicine and Cardiology Fellowship training at the University of Toronto. Following this, he did an Interventional Cardiology Fellowship at the Toronto Hospital. In 1997, Dr. Mehta accepted a Research Fellowship position in Clinical Epidemiology and Clinical Trials Methodology within the Preventive Cardiology and Therapeutics Program at McMaster University, Hamilton, Canada. In 1998, he was awarded a Heart and Stroke Foundation of Canada Research Fellowship Award. He is currently completing his Masters of Clinical Epidemiology at McMaster University.

Dr. Mehta is currently on Faculty at McMaster University as Assistant Professor of Medicine and he is a Staff Interventional Cardiologist at Hamilton Health Sciences Corporation. He is also Director of the Coronary Care Unit at McMaster University Medical Centre.

Dr. Mehta's research focuses on antiplatelet and antithrombotic therapies in acute coronary syndromes, and percutaneous coronary intervention. He is currently involved in the conduct of several large international clinical trials including CURE and CREATE.

He has published original clinical research papers in leading scientific publications, including The Lancet, Circulation, Journal of the American College of Cardiology , and the European Heart Journal .

He is a Fellow of the Royal College of Physicians and Surgeons of Canada, and of the American College of Cardiology.

Return to top of page


Professor Keith Fox is Duke of Edinburgh Professor of Cardiology of the University of Edinburgh and Head of Medical and Radiological Sciences.

Previous posts he has held include Assistant Professor in Internal Medicine (cardiology) at Washington University School of Medicine, St. Louis, USA, and Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff.

Professor Fox is a member of several professional societies. He was a founding fellow and is on the Scientific Committee of the European Society of Cardiology. In addition, he is a member of the Council on Basic Science of the American Heart Association and a Council member of the British Cardiac Society.

Professor Fox has published extensively in the area acute coronary artery disease and antithrombotic therapy and is on the editorial board of Coronary Artery Disease and Cardiology in Practice. He is Chairman of the RITA-3 trial and was Vice-chairman and UK co-ordinator of the OASIS study of hirudin versus heparin in unstable angina and for studies on low molecular heparin and glycoprotein IIb/IIIa receptor antagonists. He is currently the co-chair of the CURE Steering Committee.

The inhibition of coronary thrombosis, platelet mechanisms and haemostatic markers in unstable angina, and antioxidant vitamins and the risk of subsequent clinical events in unstable angina and myocardial infarction form Professor Fox's current research interests.

Return to top of page


Susan Chrolavicius is a Research Associate at McMaster University, Hamilton, Ontario and is the coordinator of the CURE study. Susan is a member of the CURE Steering Committee, which was responsible for study design, development of the study protocol, and implementation of the protocol. She has been responsible for the overall coordination of the work performed across 482 clinical centres in the 28 countries involved in CURE. She has worked exclusively on CURE since the summer of 1998 and has been involved in case report form design, implementation of the central randomization system, data management activities, clinical centre and sponsor liaison etc., throughout the duration of the study.

Susan first trained as a registered nurse and had substantial critical care nursing experience before pursuing a degree in Economics from McMaster University. She then joined the Clinical Trials Methodology Group at McMaster under the directorship of Professor Michael Gent where she gained considerable in-depth experience in large international clinical trials (CAMIAT and CAPRIE). She joined the Canadian Cardiovascular Collaboration (CCCF) Project Office, Population Health Institute, McMaster University under the directorship of Dr. Salim Yusuf in 1997. Susan has been the co-author of original clinical papers published in leading scientific publications such as the Lancet and the European Heart Journal .

She is a member of the Society for Clinical Trials and holds a nurses' registration at the College of Nurses of Ontario.

Return to top of page